drugset / Trial / NCT03000634
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will compare the effectiveness and safety of maintenance therapy with continuous bortezomib, lenalidomide, and dexamethasone (VRD) compared to maintenance therapy that alternates VRD with Elotuzumab, lenalidomide, and dexamethasone (Elo RD) every eight weeks.
Timeline
- Start
- 2017-04-01
- Primary completion
- 2017-04-01
- Completion
- 2017-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elotuzumab | Monoclonal antibody | 10 mg | Intravenous |
| Background | Bortezomib | Small molecule | 1.3 mg | Subcutaneous |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |
| Background | Lenalidomide | Other / unclassified | 25 mg | Oral |